Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2013 - 2026)

Theravance Biopharma (TBPH) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $472.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 37.47% year-over-year to $472.3 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 27.09% YoY), while the FY2025 annual figure was $485.6 million, up 37.1% from the prior year.
• Liabilities and Shareholders Equity retreated to $472.3 million in Q1 2026 per TBPH's latest filing, from $485.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $763.5 million in Q3 2022 and bottomed at $343.6 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $438.5 million across 5 years, with a median of $413.6 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 89.4% — and 2023, when it sank 45.83%.
• Theravance Biopharma's Liabilities and Shareholders Equity stood at $607.4 million in 2022, then sank by 37.11% to $382.0 million in 2023, then declined by 7.29% to $354.2 million in 2024, then jumped by 37.1% to $485.6 million in 2025, then slipped by 2.73% to $472.3 million in 2026.
• Business Quant data shows TBPH's Liabilities and Shareholders Equity at $472.3 million in Q1 2026, $485.6 million in Q4 2025, and $415.5 million in Q3 2025.